… 10) is the fourth-generation EGFR inhibitor obtained by high-throughput screening (HTS)
strategy from a library of 2.5 million compounds at 1 µM ATP concentration. EAI001 57 is a …

… epithelial-derived tumors, and associated with poor prognosis and survival in cancer patients.
Here, we discuss in detail the role of EGFR in specific epithelial-derived … -EGFR therapies. …

… EGFR inhibition in second-line therapy of mCRC patients after progression from first-line
treatment … Third-line treatment in patients with RAS WT mCRC who obtained a PR/CR in first …

… epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors… tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human …

… EGFR inhibition using drug combinations for TNBC treatment. Since multigeneration EGFR
tyrosine kinase inhibitors (TKIs) and anti-EGFR … platelet-derived growth factor receptor beta (…

… As the significant approach in the cancer targeted therapy, synthetic EGFR-TKIs have been
… conclusion, EGFR-TKIs are the standard first-line treatment to patients with advanced EGFR-…

… We will derive and display ranking probabilities for each treatment using the Surface Under
the … Overall, there was a lack of data on the OS benefit of EGFR inhibitors, but with a low …

… do not respond to the anti-EGFR therapies and why still other … The epidermal growth factor
receptor (EGFR) has served as … (acquired) resistance to EGFR inhibitors, including mAbs, are …

… of patient-derived NSCLC cell … of EGFR was inhibited in each cell line following treatment
with afatinib or neratinib. In contrast, only Ex19Del showed EGFR inhibition following treatment …

… We investigated the genomic landscape of EGFR amplification in blood-derived cell-free …
who received EGFR inhibitors. Incorporating EGFR inhibitors into the treatment regimens of …